Article Information
- Received August 26, 1997
- Accepted September 12, 1997
- First published December 1, 1997.
- Version of record published December 1, 1997.
Author Information
- 1Consiglio Nazionale delle Ricerche, Center of Cellular and Molecular Pharmacology, Department of Medical Pharmacology, University of Milan, 20129 Milan, Italy,
- 2Department of Neurobiology and Behavior, Cornell University, Ithaca, New York 14853, and
- 3Institute of Pharmacology, School of Medicine, University of Verona, 37134 Verona, Italy
Author contributions
Disclosures
- Received August 26, 1997.
- Accepted September 12, 1997.
This work is supported by NATO Grant CGR.960655, Telethon Italy Grant 764, Biomed Grant Project CT-931100 to G.F., and National Institutes of Health Grant NS09315 to M.M.S. C.S. is supported by Telethon Italy (Dottorato in Farmacologia e Tossicologia, University of Milan). We thank Profs. S. Tzartos (Pasteur Institute Hellenique, Athens, Greece) and S. C. Froehner (University of North Carolina, Chapel Hill, NC) for the gift of some of the mAbs used in this study, Dr. Steven Heinemann (Salk Institute, La Jolla, CA) for the gift of AChR subunit constructs, Rui Lin for help in characterizing the 52Abε antibody, Profs N. Borgese and F. Clementi for valuable support and critical reading of this manuscript, and Dr. Joel Stiles for help in computer image processing.
Correspondence should be addressed to Prof. Guido Fumagalli, Institute of Pharmacology, School of Medicine, Ospedale Policlinico Borgo Roma, 37134 Verona, Italy.
Online Impact